The CBR3 (carbonyl reductase 3) antibody is a tool used to study the CBR3 enzyme, a member of the short-chain dehydrogenase/reductase (SDR) superfamily. CBR3 catalyzes NADPH-dependent reduction of carbonyl groups, playing a role in metabolizing endogenous and exogenous substrates, including prostaglandins, steroids, and xenobiotics. It is particularly notable for its involvement in the inactivation of anthracycline chemotherapeutics (e.g., doxorubicin), influencing drug efficacy and toxicity. Dysregulation of CBR3 has been linked to cancer progression, chemoresistance, and metabolic disorders, making it a target for therapeutic and diagnostic research.
The CBR3 antibody enables detection and quantification of CBR3 protein expression in tissues or cell lines, aiding investigations into its tissue-specific roles, enzymatic activity, and interactions. Researchers employ it in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to explore CBR3's localization and expression patterns in diseases such as breast cancer, hepatocellular carcinoma, and neurodegenerative conditions. Additionally, genetic polymorphisms in CBR3 affecting enzyme activity have prompted studies using the antibody to correlate protein levels with patient-specific drug responses or disease susceptibility. Its utility extends to preclinical models for evaluating CBR3's role in oxidative stress, detoxification pathways, and metabolic syndromes, highlighting its relevance in both basic research and translational medicine.